Eton Pharma officer plans sale of 25,000 shares

Eton Pharmaceuticals, Inc. (ETON) has an affiliated officer, David Krempa, filing a Rule 144 notice to sell up to 25,000 shares of common stock through Raymond James & Associates, Inc. The planned sale on 08/24/2026 is tied to a stock option exercise for cash.

Rhea-AI Filing Summary

Eton Pharmaceuticals, Inc. (ETON) has an affiliated officer, David Krempa, filing a Rule 144 notice to sell up to 25,000 shares of common stock through Raymond James & Associates, Inc. The planned sale on 08/24/2026 is tied to a stock option exercise for cash.

During the prior three months, Krempa reported sales of 37,524 shares of Eton common stock on 05/26/2026 for $1,180,201.00 and 19,679 shares on 05/27/2026 for $618,569.00. The shares are listed on Nasdaq, and Raymond James is identified as the broker handling the proposed transaction.

Key Figures

Planned shares to be sold: 25,000 shares Prior sale on 05/26/2026: 37,524 shares for $1,180,201.00 Prior sale on 05/27/2026: 19,679 shares for $618,569.00 +1 more

4 metrics

Planned shares to be sold 25,000 shares Common stock proposed to be sold by David Krempa under Rule 144

Prior sale on 05/26/2026 37,524 shares for $1,180,201.00 Common stock sold by David Krempa during past three months

Prior sale on 05/27/2026 19,679 shares for $618,569.00 Common stock sold by David Krempa during past three months

Planned transaction date 08/24/2026 Date associated with stock option exercise and proposed sale

Key Terms

Rule 144, Stock Option Exercise, attorney-in-fact

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Stock Option Exercise financial

"Common | 08/24/2026 | Stock Option Exercise | Issuer"

A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.

attorney-in-fact regulatory

"as attorney-in-fact for David Charles Krempa"

An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for ETON?

The filing discloses that officer David Krempa intends to sell up to 25,000 shares of Eton Pharmaceuticals, Inc. common stock under Rule 144, through Raymond James & Associates, Inc., in connection with a stock option exercise for cash dated 08/24/2026.

How many ETON shares has David Krempa sold in the past three months?

Over the past three months, David Krempa reported selling 37,524 shares on 05/26/2026 for $1,180,201.00 and 19,679 shares on 05/27/2026 for $618,569.00, all in Eton Pharmaceuticals, Inc. common stock.

What is the size of the proposed ETON share sale in this Form 144?

The notice covers a proposed sale of up to 25,000 shares of Eton Pharmaceuticals, Inc. common stock. The broker listed is Raymond James & Associates, Inc., and the transaction is associated with a stock option exercise on 08/24/2026.

What type of transaction is associated with the planned ETON share sale?

The planned sale of Eton Pharmaceuticals, Inc. shares is associated with a Stock Option Exercise for cash, with an intended transaction date of 08/24/2026. This is disclosed in the securities-to-be-sold section of the notice.

On which market are ETON shares involved in this Form 144 listed?

The common shares referenced in this Form 144 for Eton Pharmaceuticals, Inc. are listed on Nasdaq, as indicated in the securities information section of the notice.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/24/2026 - 04:20 PM EDT Accepted by SEC EDGAR 08/24/2026 - 04:19 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001968254
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Eton Pharmaceuticals, Inc.
SEC File Number	001-38738
Address of Issuer	21925 W. FIELD PARKWAY SUITE 235 DEER PARK ILLINOIS 60010-7278
Phone	(847) 787-7361
Name of Person for Whose Account the Securities are To Be Sold	Krempa David
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Raymond James and Associates 880 Carillon Parkway St. Petersburg FL 33716	25000	1626750.00	28580000	08/24/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/24/2026	Stock Option Exercise	Issuer			25000	08/24/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
David Krempa 29125 W FIELD PARKWAY suite 235 DEER PARK IL 60010	Common	05/26/2026	37524	1180201.00
David Krempa 29125 W FIELD PARKWAY Suite 235 DEER PARK IL 60010	Common	05/27/2026	19679	618569.00

144: Remarks and Signature

Remarks
Date of Notice	08/24/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Rashida Mitchell, as duly authorized representative of Raymond James & Associates, Inc., as attorney-in-fact for David Charles Krempa
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)